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Abstract Background: Histological-
ly, tumors of the anal region are ei-
ther keratinizing (K) or non-kerati-
nizing (NK) squamous cell carcino-
mas (SCCA). We hypothesized that
these two variants might represent,
not only morphologically, but also
biologically, dissimilar malignancies.
The present study was undertaken to
compare the expression of apoptosis-
regulating proteins Bcl-2 and p53 in
K versus NK SCCA. Methods: We
performed an immunohistochemical
analysis on 98 pre-treatment biopsies
of patients with anal canal cancers.
Tissue sections were examined im-
munohistochemically for expression
of proteins Bcl-2 (clone 124, DAKO,
1:100) and p53 (clone DO7, DAKO,
1:200). Expression of p53 and Bcl-2
was considered positive when >5%
of tumor cells were stained. Tumor
histology was correlated with protein
expression as well as with other
clinical variables. Results: There
were 64 NK and 34 K SCC. The
proportion of Bcl-2 positive tumors
was statistically higher in NK carci-
nomas (51.5 vs. 23.5%, p=0.009). In
addition, women were more likely
than men to present with NK carci-
nomas (71 vs. 45%, p=0.03) as well
as with Bcl-2 positive tumors (47 vs.
29%, p=0.05). The more distal the
tumor is (anal margin), the more
frequently the keratinizing subtype
is observed (87 vs. 23%, p=0.0002).
By contrast, there was no correla-
tion between p53 and tumor histolo-
gy (p=0.83). Conclusions: Our data
demonstrate that non-keratinizing
and keratinizing SCCA differ in their
Bcl-2 expression. In addition, signif-
icant differences were observed in
the distribution of these two histo-
logical subtypes according to gender
and tumor sublocation. These find-
ings may indicate possible differ-
ences in the carcinogenesis process of
these two histological subtypes.
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Introduction
Considerable confusion in the literature arises from the
use of different anatomic definitions of the anal area: anal
cancer may arise from the anal canal or from the anal
margin. Eighty-five percent of anal cancers occur in the
anal canal and 15% in the anal margin [1]. The problem
with this anatomical distribution is of more than academic
interest, since anal margin tumors behave like skin cancer
and may differ in their oncological outcomes [2, 3]. Sim-
ilarly, confusion arises with regard to the histological
classification of anal canal cancers. Tumors arising within
the transitional zone were referred as junctional, basaloid
or cloacogenic. These terms have been abandoned and,
histologically, tumors of the anal canal are now referred
as either keratinizing (K) or non-keratinizing (NK) squa-
mous cell carcinomas (SCCA) [4, 5].
By recognizing that non-keratinizing and keratiniz-
ing SCCA have a similar clinical outcome, it is general-
ly assumed that both variants are biologically identical.
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The molecular biology of anal cancer is poorly under-
stood, but epidemiological studies have clearly demon-
strated that infection with high-risk human papillomavirus
(hrHPV) is responsible for the majority of cases [6, 7].
Recently, Frisch et al. reported increasing hrHPV posi-
tivity in tumors located in the proximal portion of the anal
canal, and keratinizing tumors were less likely to be
hrHPV positive than non-keratinizing tumors (OR=9.3)
[8]. Moreover, the disruption of the p53 tumor suppressor
pathway by human papillomavirus (HPV) E6 oncoprotein
is considered a key event in anal and cervical carcino-
genesis [9]. Others key players in regulating the apoptotic
pathway are the Bcl-2 genes family [10]. Expression of
the Bcl-2 gene has been shown to effectively confer re-
sistance to programmed cell death in a variety of tumors,
and a highly significant association between hrHPV in-
fection and Bcl-2 overexpression has been described [11].
Since keratinization appears to be less associated with
hrHPV infection, we hypothesized that keratinizing and
non-keratinizing SCCA may differ biologically in their
expression of some apoptosis-regulating proteins. This
study was undertaken to characterize the expression of
Bcl-2 and p53 in SCCA, according to the histological
subtypes as recently defined: keratinizing versus non-
keratinizing.
Materials and methods
Patients
Patient selection for this study was based on the availability of
adequate pre-treatment paraffin blocks. From January 1976 to
November 1998, we identified 98 adequately embedded biopsy
specimens. All tumors were classified according to the 1997 stag-
ing system of the Union Internationale Contre le Cancer (UICC,
1997). Patients’ characteristics are presented in Table 1. The fol-
lowing clinico-pathological parameters were considered for anal-
ysis: demographics (age, gender); location of the tumor (anal canal
vs. anal margin vs. overlapping); histological grade (keratinizing
vs. non-keratinizing); and tumor stage according to the tumor-node-
metastasis (TNM) classification.
Pathology and immunohistochemistry
An experienced pathologist (M.-A. B.) reviewed all pre-treatment
biopsies. Tumors were classified as keratinizing or non-keratinizing
SCCA according to one of the recommendations of the WHO cri-
teria [12]. Thus, tumors previously considered junctional, basaloid
or cloacogenic were defined as non-keratinizing SCCA except
those presenting with keratinizing features. For the immunohisto-
chemistry, formalin-fixed and paraffin-embedded tissue blocks
were cut at 4 mm and mounted on silane-coated glass slides. Im-
munohistochemical stains were performed applying a standard
ABC technique for Bcl-2 (clone 124, DAKO, 1:100) and p53 (clone
DO7, DAKO, 1:200). Heat-induced antigen retrieval was done
using a microwave oven (600 W, 35 min) and citrate buffer
(0.01 M, pH 6) for Bcl-2, while p53 was retrieved by using a
pressure cooker (3 min). After cooling down and washing, slides
were incubated with the primary antibody for 30 min at room
temperature. Following another washing cycle, slides were incu-
bated with biotinylated secondary antibody (biotinylated rabbit
anti-mouse Immunoglobulins, F(ab0)2, DAKO E0413) for 30 min,
and after washing with a streptavidin–biotinylated-HRP complex
(StreptABComplexes, DAKO K0377). Slides were washed thor-
oughly, and then incubated with diaminobenzidine used for visu-
alization.
Evaluation of immunohistochemical stains was done by one of
the authors (M.-A. B.). Results were assessed using a semi-quan-
titative score based on the estimated percentage of positive cells:
0 = 0%; 1 = <5%; 2 = 5–50%; 3 = 50–90%; and 4 = >90%. Tumors
were then classified into two groups according to the level of
expression of the protein considered (low/negative = negative or
high/positive = positive). Expression of p53 and Bcl-2 proteins was
considered positive if >5% of the malignant cells were stained
(score 2–4). Staining in <5% of tumor cells (score 0–1) was con-
sidered to be negative expression.
Statistical analysis
Group comparisons were made using the chi-square or Fisher’s
exact test (two-sided) for categorical variables, and the Mann–
Whitney U test for continuous variables. Any p values less than or
equal to 0.05 were considered statistically significant. All analyses
were performed with StatView V 5.0.1 software.
Results
Immunostaining
Regarding the expression of Bcl-2, 40 tumors showed
no staining, and 17 tumors demonstrated staining in less
than 5% of cells. Thus, Bcl-2 expression was considered
negative in 57 patients (58%) and positive in 41 patients
(42%). For the expression of p53, 42 tumors had a neg-
ative expression (43%) and 56 (57%) a positive expres-
sion.
Table 1 Patients’ clinico-pathological characteristics (n=98)
Characteristic Number (%)
Median age in years; range 68; 41–86
Male/female 22/76
Tumor location
Anal canal 72 (73.5)
Anal margin 8 (8.1)
Both (overlapping) 18 (18.4)
Tumor histology
Keratinizing 34 (34.7)
Non-keratinizing 64 (65.3)
Tumor stage (UICC 1997)
T1–T2 60 (61.2)
T3–T4 38 (38.8)
N0 74 (75.5)
N1–N3 22 (22.5)
Nx 2 (2)
P53 expression
Positive 56 (57.1)
Negative 42 (42.9)
Bcl-2 expression
Positive 41 (41.8)
Negative 57 (58.2)
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Clinico-patho-biological associations
The relationships between the clinico-biological tumor
characteristics and the histological subtype (keratinizing
vs. non-keratinizing SCCA) are summarized in Table 2.
While no differences existed according to the median age,
female patients presented a significantly higher proportion
of the non-keratinizing subtype than male patients (71 vs.
45%, p=0.03). Moreover, there was a highly significant
difference in the distribution of the two histological sub-
types according to the tumor sublocation (p=0.0002). The
more distal the tumor is (anal margin) the more the
keratinizing subtype is observed (87 vs. 23%).
Positive expression of Bcl-2 was observed in a sig-
nificantly higher proportion of non-keratinizing tumors
than the keratinizing subtype (51.5 vs. 23.5, p=0.009). On
the other hand, no significant association was observed
between p53 expression and the histological subtype
(p=0.83).
Positive expression of Bcl-2 was more frequent in fe-
males than in male patients (47 vs. 29, p=0.05). This
result is in accordance with the fact that non-keratinizing
tumors are more prevalent in female than in male patients.
Discussion
We report a relatively large series of patients presenting
with SCCA who were managed in a one institution; the
male/female ratio (1/3), the median age at diagnosis
(68 years) are in accordance with the epidemiology of
these tumors prior to the HIV era [13]. Similarly, the
distribution of tumors within the anus (ration margin/ca-
nal = 1/4), as well as the higher proportion of non-kera-
tinizing tumors are consistent with larger previously
published series in Europe [14]. Our data indicate that
Bcl-2 and p53 proteins are expressed in 42% and 57% of
SCCA respectively. Bcl-2 positive expression was sig-
nificantly associated with non-keratinizing SCCA. In
addition, women presented with a higher proportion of
Bcl-2-positive tumors. By contrast, p53 protein expres-
sion was not significantly related to tumor histology.
The sequence of epithelial zones within the anal canal
is anal transitional zone (ATZ), non-keratinized squamous
epithelium, and squamous epithelium [15]. In the most
recent classification of anal cancers, it has been recom-
mended that the generic term anal squamous cell carci-
noma be used for all previous subtypes of anal cancers,
namely basaloid, transitional, large-cell keratinizing,
and large-cell non-keratinizing [12]. This simplification,
however, does not signify that all SCCA are similar,; our
data clearly indicate that the higher the tumor is located
within the anal region, the higher the proportion of tumor
expressing the anti-apoptotic protein Bcl-2.
Obviously, larger series are needed to determine
whether these differences may have an impact on the
prognosis or on the response to chemoradiation protocols.
What can be inferred, however, from the abundant liter-
ature regarding SCC of the uterine cervix, is that:
1. Bcl-2 overexpression is a risk factor for the progres-
sion of HPV-related lesions [16]
2. Bcl-2 expression is associated with a poor response to
chemotherapy [17]
3. Bcl-2 is a strong independent prognostic parameter for
overall survival [18]
Whether these data on uterine cervix carcinoma can be
translated to SCCA remains hypothetical. We previously
correlated the expression of various apoptosis-regulating
proteins with the response to chemoradiation in patients
with anal cancer [19]. Surprisingly, the lack of Bcl-2 ex-
pression was significantly correlated with poorer disease-
free survival. Conflicting data from the literature demon-
strate that tumor response (or resistance) to chemoradiation
is a complicated process that is unlikely to be controlled
by a single molecule, or even by a single protein family.
However, our results strongly suggest that, from a biolog-
ical standpoint, tumors originating from the supradentate
anal canal may represent a distinct entity, characterized by
an increased expression of anti-apoptotic protein Bcl-2.
In summary, our data demonstrate that non-keratiniz-
ing and keratinizing SCCA differ in their expression of
the anti-apoptotic protein Bcl-2. This finding should alert
clinicians and pathologists to the risks related to over-
simplification in the histological classification of these
tumors. Indeed, these results may indicate possible dif-
ferences in the carcinogenesis process of these two his-
tological subtypes. Thus, we recommend for future clin-
ical studies that the histopathological terminology of
SCCA should still consider the degree of keratinization in
order to identify potential differences in prognosis.
Table 2 Comparison of keratinizing (n=34) versus non-keratiniz-
ing (n=64) squamous cell carcinomas (SCCA)
Keratinizing
(%)
Non-keratinizing
(%)
p value
Age, median; range 68; 41–85 67; 41–86 0.2
Gender 0.03
Male 12 (35) 10 (16)
Female 22 (65) 54 (84)
Tumor location 0.0002
Anal canal 19 (56) 53 (82.5)
Anal canal + margin 8 (24) 10 (16)
Anal margin 7 (20) 1 (1.5)
Tumor stage 0.7
T1–T2 20 (59) 40 (62.5)
T3–T4 14 (41) 24 (37.5)
P53 expression 0.83
Positive 20 (59) 36 (56)
Negative 14 (41) 28 (44)
Bcl-2 expression 0.009
Positive 8 (23.5) 33 (51.5)
Negative 26 (76.5) 31 (48.5)
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